Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Novo Nordisk has filed for regulatory approval in both the U.S. and Europe to update the labelling of oral semaglutide to ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...